SCHEMBL26773164

SCHEMBL26773164

NC(=O)c1nn(-c2c(F)cccc2Cl)cc1Nc1ccc(C(=O)N2CCOCC2)cc1

nearest known ligand 0.61

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ TYK2 P29597 5/20 0.61
▸ JAK2 O60674 5/20 0.61
▸ JAK1 P23458 4/20 0.61
▸ JAK3 P52333 4/20 0.61
▸ NTRK1 P04629 1/20 0.43
▸ HPGD P15428 2/20 0.43
▸ TSHR P16473 1/20 0.43
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ LRRK2 Q5S007 1/20 0.42
▸ NPC1 O15118 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ LMNA P02545 1/20 0.42
▸ MAPT P10636 1/20 0.42
▸ HTT P42858 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ BTK Q06187 9/20 0.42
▸ EPHX2 P34913 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30486356 1.00 TYK2 (0.61) TYK2JAK2JAK1JAK3NTRK1
SCHEMBL26776628 0.94 TYK2 (0.60) TYK2JAK2JAK1JAK3HPGD
SCHEMBL26776680 0.94 JAK2 (0.56) TYK2JAK2JAK1JAK3HPGD
SCHEMBL26773365 0.92 TYK2 (0.50) TYK2JAK2JAK1JAK3HPGD
SCHEMBL30486270 0.92 TYK2 (0.50) TYK2JAK2JAK1JAK3HPGD
SCHEMBL30486259 0.91 TYK2 (0.49) TYK2JAK2JAK1JAK3HPGD
SCHEMBL26773367 0.91 TYK2 (0.49) TYK2JAK2JAK1JAK3HPGD
SCHEMBL30486370 0.90 JAK2 (0.52) TYK2JAK2JAK1JAK3NTRK1
SCHEMBL26773590 0.90 JAK2 (0.52) TYK2JAK2JAK1JAK3NTRK1
SCHEMBL30486380 0.90 CCNT1 (0.49) TYK2JAK2JAK1JAK3NTRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230373985-A1 KINASE MODULATORS AND METHODS OF USE THEREOF ORIGENIS GMBH (DE) 2023-11-23 — — US disclosed
US-20230373985-A1 KINASE MODULATORS AND METHODS OF USE THEREOF ORIGENIS GMBH (DE) 2023-11-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373985-A1 KINASE MODULATORS AND METHODS OF USE THEREOF TYK2, MAPKAPK2, MAP3K20 TYK2 1/4885JAK2 89/4885JAK1 34/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback